Clinical Trials
34 trialsUse of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
H. Lee Moffitt Cancer Center and Research Institute
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
BEVANEC
Hospices Civils de Lyon
68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)
Radio Isotope Therapy of America
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
M.D. Anderson Cancer Center
NIPINEC
Intergroupe Francophone de Cancerologie Thoracique
Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma
Peking University
NET02
The Christie NHS Foundation Trust
AcSé
UNICANCER
RAPNEN
Catholic University of the Sacred Heart
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
SCRI Development Innovations, LLC
Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma
SCRI Development Innovations, LLC
TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors
Asan Medical Center
DParcoursDig
Institut Curie
Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy
M.D. Anderson Cancer Center
EBRT
Sunnybrook Health Sciences Centre
AveNEC
Johannes Gutenberg University Mainz
EVINEC
AIO-Studien-gGmbH
TENEC
National Cancer Institute, Naples
Inhaled Essential Oil Effect on Common QOL Concerns During Cancer Treatment
Ohio State University Comprehensive Cancer Center
NET-001
Sunnybrook Health Sciences Centre
MS100070-0177
Samsung Medical Center
Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)
Haukeland University Hospital
KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors
Gabrail Cancer Center Research
Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients
National Health Research Institutes, Taiwan
Clinical Trial of the Impact of Treatment Consultation Recordings on Cancer Patient Outcomes
University of Manitoba
Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
Yale University
68Ga
Vanderbilt-Ingram Cancer Center
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
SCRI Development Innovations, LLC
Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma
M.D. Anderson Cancer Center
Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples
University of Western Ontario, Canada
Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract
M.D. Anderson Cancer Center
5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors
University of Turin, Italy